Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma a phase II LYSA study

Roch Houot 1, 2 Guillaume Cartron 3 Fontanet Bijou Sophie de Guibert 1, 2 Gilles A Salles 4 Christophe Fruchart 5 Krimo Bouabdallah 6 Marie Maerevoet Pierre Feugier 7 Steven Le Gouill 8, 9 Hervé Tilly 10 Rene-Olivier Casasnovas 11 Cécile Moluçon-Chabrot 12 Eric van den Neste 13 Pierre Zachee 14 Marc Andre Christophe Bonnet 15 Corinne Haioun 16 Achiel van Hoof Koen van Eygen 17 Lysiane Molina 18 Emmanuelle Nicolas-Virelizier 19 Philippe Ruminy 10 Franck Morschhauser 20
Document type :
Journal articles
Complete list of metadatas

Cited literature [5 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01903056
Contributor : Laurent Jonchère <>
Submitted on : Tuesday, November 13, 2018 - 11:15:31 AM
Last modification on : Friday, September 13, 2019 - 4:22:06 PM

File

Houot_Obinutuzumab plus Lenali...
Files produced by the author(s)

Identifiers

Citation

Roch Houot, Guillaume Cartron, Fontanet Bijou, Sophie de Guibert, Gilles A Salles, et al.. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma a phase II LYSA study. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2018, 33 (3), pp.776-780. ⟨10.1038/s41375-018-0282-y⟩. ⟨hal-01903056⟩

Share

Metrics

Record views

174

Files downloads

132